Open an account

Lipella Pharmaceuticals

LIPO · NASDAQ

$0.0005+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About LIPO

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The firm is addressing two indications via the development of its product candidates, which it has designated as LP-10 for the indication of hemorrhagic cystitis (HC) and LP-310 for the indication of oral lichen planus (OLP), which is chronic, uncontrolled urinary blood loss that results from certain chemotherapies (such as alkylating agents) or pelvic radiation therapy (also called radiation cystitis). In the third program, the Company is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). In a fourth program, the Company is also developing an intravesical formulation of immunoglobulins including checkpoint inhibitors, referred to as LP-50.

Employees
5
Headquarters
Pittsburgh, Pennsylvania
Listed
Dec 20, 2022
Sector
Health Care
Industry
Biotechnology
Website
lipella.com

LIPO key statistics

Market cap
2.31K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
677
Volume
310
Open price
$0.0005
High today
$0.0005
Low today
$0.0005
52 Week high
$0.628
52 Week low
$0.0002

Lipella Pharmaceuticals (LIPO) at a glance

As of Oct 20, 2026, Lipella Pharmaceuticals (LIPO) shares are priced at $0.0005, giving the company a market cap of 2.31K and a price-to-earnings ratio of 0.00.

Volume so far is 310 shares, below the average of 677 shares a day.

Over the past year Lipella Pharmaceuticals has ranged from $0.0002 to $0.628, and now sits 0% of the way up that range.

Lipella Pharmaceuticals met or beat analyst EPS estimates in 1 of the last 2 quarters. In Q4 FY24 it reported -$1.19 per share against an estimate of -$2.48.

LIPO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 2 quarters, by 52.0% on average.

  1. Q3 FY24: reported -$1.29 per share against an estimate of -$0.9792
  2. Q4 FY24: reported -$1.19 per share against an estimate of -$2.48

LIPO news

  • Press releasePRNewswire

    Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus

  • Avi Kapoor

    Crude Oil Falls 1%; US Services PMI Declines In June

  • Avi Kapoor

    Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Market-Moving News for February 11th

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as Lipella Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.